Lancet
-
Randomized Controlled Trial Multicenter Study Comparative Study
The price of blood is measured in iron.
-
Randomized Controlled Trial Multicenter Study
Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.
Pregnant women with type 1 diabetes are a high-risk population who are recommended to strive for optimal glucose control, but neonatal outcomes attributed to maternal hyperglycaemia remain suboptimal. Our aim was to examine the effectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neonatal health outcomes. ⋯ Juvenile Diabetes Research Foundation, Canadian Clinical Trials Network, and National Institute for Health Research.
-
Randomized Controlled Trial Multicenter Study
Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors.
Limits on the frequency of whole blood donation exist primarily to safeguard donor health. However, there is substantial variation across blood services in the maximum frequency of donations allowed. We compared standard practice in the UK with shorter inter-donation intervals used in other countries. ⋯ NHS Blood and Transplant, National Institute for Health Research, UK Medical Research Council, and British Heart Foundation.
-
Randomized Controlled Trial Comparative Study
Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial.
Abdominal aortic aneurysm is the only cardiovascular disease targeted by population screening. In this study, we test the effect of screening and subsequent intervention for abdominal aortic aneurysm, peripheral arterial disease, and hypertension combined. ⋯ The 7th European Framework Programme, Central Denmark Region, Viborg Hospital, and the Danish Council for Independent Research.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population. ⋯ Eli Lilly and Company.